8-KEarnings & ResultsExhibits & Filings

Elevance Health, Inc. 8-K Report, Financial Results (Oct 19, 2022)

Filed October 19, 2022For Securities:ELV

Summary

Elevance Health, Inc. (ELV) filed an 8-K on October 19, 2022, primarily to furnish a press release detailing its financial results for the third quarter ended September 30, 2022. This filing serves as a notification to investors about the company's performance and provides access to the detailed financial information released to the public. Investors should review the furnished press release (Exhibit 99.1) for specific operational and financial metrics, as it contains the core data discussed in this report. The report itself doesn't introduce new financial data but directs readers to the press release for the official results. It also includes standard forward-looking statement disclaimers, outlining potential risks and uncertainties that could affect future performance. These include factors such as healthcare costs, regulatory changes, market conditions, and operational risks, which are critical for investors to consider when assessing the company's outlook.

Key Highlights

  • 1Furnished press release containing Q3 2022 financial results (Exhibit 99.1).
  • 2Event date of the financial results release was October 18, 2022, filed on October 19, 2022.
  • 3The 8-K is primarily a notification and reference document for the press release, not an addition of new financial statements.
  • 4Information furnished is not deemed 'filed' for Section 18 of the Securities Exchange Act of 1934.
  • 5Standard forward-looking statement disclaimers are included, warning of potential risks and uncertainties.
  • 6Potential risks highlighted include impacts of large-scale medical emergencies, healthcare costs, regulatory changes (ACA, Medicare/Medicaid), market conditions, cyber security breaches, and competitive pressures.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially furnish Elevance Health's press release containing its financial results for the third quarter ended September 30, 2022. It acts as a formal notification and provides investors with access to the detailed financial performance information that was publicly announced.

The actual financial results for the third quarter ended September 30, 2022, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. Investors should refer to this exhibit for specific financial figures and performance metrics.

No, this 8-K filing does not contain new financial statements or updated guidance itself. It primarily references and incorporates by reference the press release (Exhibit 99.1) where the Q3 2022 financial results were reported. Any specific guidance or detailed financial data would be within that press release.

The forward-looking statements section highlights various risks and uncertainties that could impact Elevance Health's future performance. These include the impact of large-scale medical emergencies (like pandemics), trends in healthcare costs and utilization, regulatory changes (including the ACA and Medicare/Medicaid), market and economic conditions, cybersecurity breaches, competitive pressures, and risks related to its pharmacy benefit management (PBM) business.